Are peptides legal in France?
The short answer
In France, named peptide medicines such as Ozempic (semaglutide), Wegovy (semaglutide) and Mounjaro (tirzepatide) are authorised, and ANSM states they are available only on prescription. Injectable products called "peptides", most often sold as vials of injectable liquid or injector pens on the internet, on social networks or through informal channels, are a different matter: ANSM states that these products have not been evaluated by the health authorities and are not authorised, calls them fraudulent products, and names retatrutide, TB500, GHK-Cu and BPC-157 among the products offered without authorisation from the health authorities. Customs limit imports of medicines by travellers to personal use only, and peptide hormones are on the 2026 World Anti-Doping Agency prohibited list that applies in sport.
Status by category
| Category | Status |
|---|---|
| Approved peptide medicines | Prescription only |
| Research peptides | Not authorised |
| Compounded preparations | Unclear |
| Cosmetics | Unclear |
| Food supplements | Restricted |
| Personal import | Restricted |
| Sport and anti-doping | Prohibited |
Approved peptide medicines Prescription only
ANSM states that Ozempic (semaglutide), indicated in insufficiently controlled type 2 diabetes, is available on prescription only, and that the GLP-1 analogues indicated in obesity, Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide), are available only on prescription. Since 23 June 2025 any doctor may start and renew these obesity treatments, within the terms of their marketing authorisation. ANSM also states that these obesity treatments must not be used for weight loss for cosmetic purposes. [2][3]
Research peptides Not authorised
ANSM states that the injectable peptides sold on the internet, on social networks or through informal channels have not been evaluated by the health authorities and are not authorised, and that they are fraudulent products, some presented as medicines without evaluation or authorisation. The agency tells the public not to buy them and not to use them, and never to use a product carrying the wording For research use only, Réservé à la recherche or Not for human use. In this context it has taken sanitary police decisions intended to ban the sale and the advertising of products presented as containing GLP-1 agonists. [1]
Compounded preparations Unclear
No specific official rule found.
Cosmetics Unclear
No specific official rule found.
Food supplements Restricted
A food supplement is a product taken by mouth, and the French orders that complete the supplements decree set positive lists of authorised substances, which in effect forbids the use of any substance not mentioned. Before it can be sold in France, a food supplement must be declared, and in some cases authorised, by the DGAL. ANSM notes that some products presented as food supplements have an action that goes beyond what is expected for that type of product. [7][1]
Personal import Restricted
Customs state that the quantities of medicines a traveller may carry must not exceed personal use, and that if the quantities exceed personal use the import is absolutely prohibited. For a medicine that is neither a narcotic nor a psychotropic, the quantity carried matches the treatment duration written on the prescription or, failing a prescription, three months of treatment, and the prescription must be produced only when the treatment duration goes beyond three months. For a narcotic or psychotropic medicine the traveller must carry it personally, the quantity must fit the treatment duration on the prescription or, failing that, one month of treatment, and a certificate from the competent authorities of the country of provenance (Schengen) or the doctor's prescription (outside Schengen) must be produced. The definition of a medicine used here is the broad one of article L 5111-1 of the public health code, by presentation or by function. [6]
Sport and anti-doping Prohibited
The French anti-doping agency publishes the 2026 World Anti-Doping Agency list of prohibited substances and methods, in force since 1 January, which indicates which substances and methods are prohibited in competition and/or out of competition and which substances are prohibited only in certain sports. That list includes category S2, peptide hormones, growth factors, related substances and mimetics, to which the example pegmolesatide was added in 2026. [5]
Peptide by peptide
| Peptide | Status | Details |
|---|---|---|
| semaglutide | Prescription only | Authorised as a medicine (Ozempic in type 2 diabetes, Wegovy in obesity) and available only on prescription. [2][3] |
| tirzepatide | Prescription only | Authorised as Mounjaro in obesity and, since 23 June 2025, prescribable and renewable by any doctor within its marketing authorisation, on prescription only. [2] |
| retatrutide | Not authorised | ANSM lists retatrutide among the products offered without authorisation from the health authorities. [1] |
| BPC-157 | Not authorised | ANSM lists BPC-157 among the products offered without authorisation from the health authorities. [1] |
| TB-500 | Not authorised | ANSM lists TB500 among the products offered without authorisation from the health authorities. [1] |
| GHK-Cu | Not authorised | ANSM lists GHK-Cu among the products offered without authorisation from the health authorities. [1] |
Change history
- Market surveillance of cosmetic products changed hands: the DGCCRF became the only authority competent to control cosmetic manufacturing and packaging establishments, a task previously shared with ANSM. [8]
- ANSM widened the prescribing conditions of the GLP-1 analogues indicated in obesity: initial prescription and renewal of Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide) became open to any doctor, within the marketing authorisation, while the medicines stay available on prescription only. [2]
- ANSM published its actions taking sanitary police measures against websites selling GLP-1 analogues. [1]
- The 2026 World Anti-Doping Agency prohibited list came into force, with pegmolesatide added as a further example in category S2, peptide hormones, growth factors, related substances and mimetics. [5]
- ANSM published a public warning on peptides sold online, telling users not to buy or use them because they have not been evaluated and are not authorised. [1]
- Sanitary police decision ordering the withdrawal of products presented as containing GLP-1 agonists, company Synedica Laboratories. [1]
- Sanitary police decision ordering the withdrawal of products presented as containing GLP-1 agonists, company AZRL LTD. [1]
Official sources
- « Peptides » vendus en ligne : ne les utilisez pas, ils peuvent être dangereux, ANSM (Agence nationale de sécurité du médicament et des produits de santé)
- Analogues du GLP-1 indiqués dans le traitement de l'obésité : l'ANSM fait évoluer leurs conditions de prescription et de délivrance, ANSM
- Ozempic (sémaglutide) : un médicament à utiliser uniquement dans le traitement du diabète de type 2, ANSM
- Bonnes pratiques de préparation (référentiel opposable, préparations magistrales, officinales et hospitalières), ANSM
- La liste des substances interdites par l'Agence mondiale antidopage en 2026, AFLD (Agence française de lutte contre le dopage)
- Le transport de médicaments en France par des particuliers, Direction générale des douanes et droits indirects (douane.gouv.fr)
- Qu'est-ce qu'un complément alimentaire ?, Ministère de l'Agriculture et de la Souveraineté alimentaire
- Les missions de surveillance du marché des cosmétiques confiées à la DGCCRF, ANSM
General information, not legal advice. Rules change: check the official source before you act.